Floatz logo

Bazedoxifene

Obesity

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedActive
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
59/ 100

Competitive context

574 Active assets in the Obesity cohort.

View all 50

Same molecule, other indications

Bazedoxifene is also rated in:

Postmenopausal SymptomsDormant
BB
Indicative ·
69 / 100
View asset →
Glucose HomeostasisDormant
BB
Indicative ·
69 / 100
View asset →
schizophreniform disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →